Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model

Journal of Clinical Investigation

Volumn 112, Issue 12, 2003, Pages 1880-1886

  Jones, Stephen C ^a   Murphy, George F ^b   Friedman, Thea M ^a   Korngold, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOPSY; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; EPITHELIUM; GRAFT VERSUS HOST REACTION; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE;

EID: 0346724480     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19427     Document Type: Article

References (50)

1. + T cells to cause lethal graft-versus-host disease across minor histocompatibility antigen barriers in mice. J. Exp. Med. 165:1522-1564.
2. Perreault, C., Roy, D.C., and Fortin, C. 1998. Immunodominant minor histocompatibility antigens: the major ones. Immunol. Today. 19:69-74.
3. Ferrara, J. L., Levy, R., and Chao, N.J. 1999. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant. 5:347-356.
4. Shlomchik, W. D., et al. 1999. Prevention of graft versus host disease by inactivation of host antigen presenting cells. Science. 285:412-415.
5. Dickinson, A.M., et al. 2002. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8:410-414.
6. Mutis, T., et al. 2002. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. Biol. Blood Marrow Transplant. 8:412-419.
7. Mapara, M.Y., et al. 2002. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 100:1903-1909.
8. Korngold, R., and Sprent, J. 1982. Features of T cells causing H-2-restricted lethal graft-vs-host disease across minor histocompatibility barriers. J. Exp. Med. 155:872-883.
9. Teshima, T., et al. 2002. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8:575-581.
10. Bruce, J., Symington, F.W., McKearn, T.J., and Sprent, J. 1981. A monoclonal antibody discriminating between subsets of T and B cells. J. Immunol. 127:2496-2501.
11. Sarmiento, M., Glasebrook, A.L., and Fitch, F.W. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt-2 antigen block T cell mediated cytolysis in the absence of complement. J. Immunol. 125:2665-2672.
12. + T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial infiltrate. Biol. Blood Marrow Transplant. 7:2-13.
13. Korngold, R., et al. 1997. Peptide analogs that inhibit IgE-Fc epsilon RI alpha interactions ameliorate the development of lethal graft-versus-host disease. Biol. Blood Marrow Transplant. 3:187-193.
14. Ferrara, J.L, Guillen, F.J., Sleckman, B., Burakoff, S.J., and Murphy, G.F. 1986. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J. Invest. Dermatol. 86:371-375.
15. Bailey, D.W., and Mobraaten, L.E. 1969. Estimates of the number of loci contributing to the histoincompatibility between C57BL-6 and BALB-c strains of mice. Transplantation. 7:394-400.
16. Mathieson, B.J., Sharrow, S.O., Bottomly, K., and Fowlkes, B.J. 1980. Ly 9, an alloantigenic marker of lymphocyte differentiation. J. Immunol. 125:2127-2136.
17. Metlay, J.P., et al. 1990. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med. 171:1753-1771.
18. Lai, L., Alaverdi, N., Maltais, L., and Morse, H.C., III. 1998. Mouse cell surface antigens: nomenclature and immunophenotyping. J. Immunol. 160:3861-3868.
19. Basak, S.K., et al. 2002. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte-colony-stimulating factor and interleukin-4. Blood. 99:2869-2879.
20. Gilliam, A.C., and Murphy, G.F. 1997. Cellular pathology of cutaneous graft-versus-host disease. In Graft-versus-host disease. 2nd edition. J.L.M. Ferrara, H.J. Deeg, and S.J. Burakoff, editors. Marcel Dekker Inc. New York, New York, USA. 291-314.
21. Jaraquemada, D., Marti, M., and Long, E.O. 1990. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II restricted cells. J. Exp. Med. 172:947-954.
22. Malnati, M.S., et al. 1992. Processing pathways for presentation of cytosolic antigen to MHC class II restricted T cells. Nature. 357:702-704.
23. Nevala, W.K., Paul, C., and Wettstein, P.J. 1998. Immunodominant minor histocompatibility antigen peptides recognized by cytolytic T lymphocytes primed by indirect presentation. Transplantation. 65:559-569.
24. Song, H.K., et al. 1999. Characterization of the alloimmune response to minor histocompatibility antigens by in vivo MLR. Transplant. Proc. 31:836-837.
25. Song, H.K., et al. 1999. Cutting edge. Alloimmune responses against major and minor histocompatibility antigens: distinct division kinetics and requirement for CD28 costimulation. J. Immunol. 162:2467-2471.
26. Hill, G.R., et al. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 90:3204-3213.
27. Cooke, K.R., et al. 1998. Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J. Clin. Invest. 102:1882-1891.
28. Krijanouski, O.I., et al. 1999. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood. 94:825-831.
29. Reddy, P., et al. 2001. Interleukin 18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194:1433-1440.
30. 1 mice. J. Immunol. 168:3065-3071.
31. Nesrel, F.P., Price, K.S., Seemayer, T.A., and Lapp, W.S. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J. Exp. Med. 175:405-413.
32. Cooke, K.R., et al. 2001. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J. Clin. Invest. 107:1581-1589.
33. McCarthy, P.L., et al. 1991. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood. 78:1915-1991.
34. Mowat, A.M., Hutton, A.K., Garside, P., and Steel, M. 1993. A role for interleukin-1α in immunologically mediated intestinal pathology. Immunology. 80:110-115.
35. Abhyankar, S., Gilliland, G., and Ferrara, J.L.M. 1993. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocomopatability antigens. Transplanatation. 56:1518-1523.
36. Brown, G.R., et al. 1999. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology. 116:593-601.
37. Stuber, E., Buschenfeld, A., Von Frier, A., Arendt, T., and Folsch, U.R. 1999. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumor necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy. Gut. 45:229-235.
38. + effector cells. Am. J. Pathol. 138:983-990.
39. Murphy, G.F., Sueki, H., Teuscher, C., Whitaker, D., and Korngold. R. 1994. Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease. J. Invest. Dermatol. 102:451-461.
40. Liu, J., et al. 2001. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood. 98:3367-3375.
41. 2 fragments in vivo modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J. Immunol. 154:5542-5554.
42. + T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant. 9:243-256.
43. Breathnach, S.M., and Katz, S.I. 1983. Keratinocytes synthesize IA antigen in acute cutaneous graft-versus-host disease. J. Immunol. 131:2741-2745.
44. Shiohura, T., Narimatsu, H., and Nagashima, M. 1987. Induction of cutaneous graft versus host disease by allo- or self-IA-reactive helper T cells in mice. Transplantation. 43:692-698.
45. Giorno, R., Choi, K.L., Katz, H.R., and Claman, H.N. 1987. Monoclonal antibody analysis of skin in chronic murine graft-versus-host disease produced across minor histocompatibility barriers. Cell Immunol. 106:76-87.
46. Sviland, L., et al. 1988. Class II antigen expression by keratinocytes and enterocytes, an early feature of graft-versus-host disease. Transplantation. 46:402-406.
47. Graubert, T.A., Dipersio, J.F., Russel, J.H., and Ley, T.J. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplant. J. Clin. Invest. 100:904-911.
48. Schmaltz, K.J., et al. 2001. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host-disease and graft-versus-leukemia. Blood. 97:2886-2895.
49. + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation. 64:571-576.
50. Murphy, G.F., and Liu, V. 1997. Dermal immune system. In Skin immune system. J.D. Bos, editor. CRC Press. New York, New York, USA. 347-363.